Monday, 9 December 2013

New anti-inflammatory

New anti-inflammatory

"Recently, there is a new anti-inflammatory for people with chronic obstructive pulmonary disease (COPD). These are Homilist (brand name Danas). The drug inhibits the activity of an enzyme that plays a role in the inflammation associated with COPD. The agent is approved in Europe and is also compensated in some countries. Brief Overview of Fat Loss Factor Program

In the Netherlands, the Health Care Insurance Board (CVZ) decided not to pay, because the beneficial effect is usually not so great. Moreover, the agent has many side effects for some people, especially for the gastrointestinal tract.

Yet for a limited category of COPD patients, I estimate hundreds, perhaps thousands, certainly an asset. For example, for people who are insufficiently responsive to other medications? It costs about € 500 per year, an amount that does not bring to everyone.

Benefit to the patient for whom the drug intolerance: less inflammation. Disadvantage: it costs € 500 per year. "

Money back - Dr. Charles Livingston

"The drug Foliar. (Active ingredient: ) suppresses allergic immune responses would expire because of doubts about the efficiency These costs are the costs between € 12,000 and € 15,000 per year Foliar has been proven effective for about 800 of the total..

500,000 asthmatics. As practitioners, we have made arrangements with the company that makes this drug and the CVZ, Foliar which remains available., we have committed to the group of patients we prescribe the drug.

No comments:

Post a Comment